Sustained-Release Fampridine (4-Aminopyridine) in Multiple Sclerosis: Efficacy and Impact on Motor Function

Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis

(2011) Craig I. Coleman et al.   CURRENT MEDICAL RESEARCH AND OPINION

Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability

(2011) Hillel Panitch et al.   EXPERT OPINION ON PHARMACOTHERAPY

Which walking capacity tests to use in multiple sclerosis? A multicentre study providing the basis for a core set

(2011) Domien Gijbels et al.   Multiple Sclerosis Journal

Community walking can be assessed using a 10-metre timed walk test

(2011) JCE Kempen et al.   Multiple Sclerosis Journal

Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis

(2010) Howard L. Zwibel   ADVANCES IN THERAPY

A phase 3 trial of extended release oral dalfampridine in multiple sclerosis

(2010) Andrew D. Goodman et al.   ANNALS OF NEUROLOGY

Dalfampridine Extended Release

(2010) Claudine M. Chwieduk et al.   CNS DRUGS

Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial

(2009) Andrew D Goodman et al.   LANCET

Reliability and validity of the Medical Research Council (MRC) scale and a modified scale for testing muscle strength in patients with radial palsy

(2008) T Paternostro-Sluga et al.   JOURNAL OF REHABILITATION MEDICINE

Patient perception of bodily functions in multiple sclerosis: gait and visual function are the most valuable

(2008) C Heesen et al.   Multiple Sclerosis Journal

Dose comparison trial of sustained-release fampridine in multiple sclerosis

(2008) A. D. Goodman et al.   NEUROLOGY